OmniAb (OABI) Free Cash Flow (2021 - 2026)
OmniAb (OABI) reported Free Cash Flow of -$5.1 million for Q1 2026, up 68.4% year-over-year from -$3.0 million in Q1 2025, and up 10.59% on a QoQ basis from -$5.7 million in Q4 2025.
OmniAb (OABI) has 6 years of Free Cash Flow data on file, last reported at -$5.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 68.4% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.0 million (up 32.11% YoY) and the FY2025 annual result came in at -$37.0 million, up 6.85% from the prior year.
- Free Cash Flow advanced to -$5.1 million in Q1 2026 per OABI's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $27.5 million in Q1 2023 and bottomed at -$17.5 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$5.3 million (2025), against an average of -$4.9 million.
- The widest annual swing landed in 2022, when Free Cash Flow slumped 333.79%; it then soared 200.73% in 2023.
- Tracing OABI's Free Cash Flow over 5 years: stood at -$3.6 million in 2022, then tumbled by 170.81% to -$9.8 million in 2023, then surged by 78.28% to -$2.1 million in 2024, then plunged by 168.07% to -$5.7 million in 2025, then increased by 10.59% to -$5.1 million in 2026.
- Per Business Quant, the three latest OABI Free Cash Flow figures stand at -$5.1 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.08 Mn |
| Mar 31, 2026 | -5.08 Mn |
| Dec 31, 2025 | -5.68 Mn |
| Dec 31, 2025 | -5.68 Mn |
| Sep 30, 2025 | -9.95 Mn |
| Sep 30, 2025 | -9.95 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Mar 31, 2025 | -16.08 Mn |
| Mar 31, 2025 | -16.08 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Sep 30, 2024 | -8.25 Mn |
| Sep 30, 2024 | -8.25 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | -17.50 Mn |
| Mar 31, 2024 | -17.50 Mn |
| Dec 31, 2023 | -9.76 Mn |
| Dec 31, 2023 | -9.76 Mn |
| Sep 30, 2023 | -5.18 Mn |
| Sep 30, 2023 | -5.18 Mn |
| Jun 30, 2023 | -10.84 Mn |
| Jun 30, 2023 | -10.84 Mn |
| Mar 31, 2023 | 27.45 Mn |
| Mar 31, 2023 | 27.45 Mn |
| Dec 31, 2022 | -3.60 Mn |
| Dec 31, 2022 | -3.60 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Mar 31, 2022 | 9.13 Mn |
| Mar 31, 2022 | 9.13 Mn |
| Dec 31, 2021 | -4.71 Mn |
| Dec 31, 2021 | -4.71 Mn |
| Sep 30, 2021 | -966,377.00 |
| Sep 30, 2021 | -966,377.00 |